Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in previously treated mantle cell lymphoma: Updated results from the phase 1/2 BRUIN study Meeting Abstract

  

Authors:	Wang, M.; Shah, N.; Alencar, A.; Gerson, J.; Patel, M.; Fakhri, B.; Jurczak, W.; Tan, X.; Lewis, K.; Fenske, T.; Coombs, C.; Flinn, I.; Lewis, D.; Le Gouill, S.; Palomba, M. L.; Woyach, J.; Pagel, J.; Lamanna, N.; Cohen, J.; Barve, M.; Ghia, P.; Eyre, T.; Zinzani, P. L.; Ujjani, C.; Koh, Y.; Izutsu, K.; Lech-Maranda, E.; Tam, C.; Sundaram, S.; Yin, M.; Nair, B.; Tsai, D.; Balbas, M.; Mato, A.; Cheah, C.
Abstract Title:	Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in previously treated mantle cell lymphoma: Updated results from the phase 1/2 BRUIN study
Meeting Title:	62nd Annual Scientific Meeting of the British Society for Haematology
Journal Title:	British Journal of Haematology
Volume:	197
Issue:	Suppl. 1
Meeting Dates:	2022 Apr 3-5
Meeting Location:	Manchester, United Kingdom
ISSN:	0007-1048
Publisher:	John Wiley & Sons
Date Published:	2022-05-01
Start Page:	101
End Page:	104
Language:	English
ACCESSION:	WOS:000776484300106
PROVIDER:	wos
PUBMED:	35362090
DOI:	10.1111/bjh.18134
Notes:	Meeting Abstract: BSH22-PO56 -- Hybrid meeting, also held virtually -- Source: Wos